A randomized controlled trial for evaluating the impact of integrating a computerized clinical decision support system and a socially assistive humanoid robot into grand rounds during pre/post-operative care

Izidor Mlakar¹, Urška Smrke¹, Vojko Flis², Andrej Bergauer², Nina Kobilica², Tadej Kampič², Samo Horvat², Damjan Vidovič², Bojan Musil³ and Nejc Plohl³

Abstract

Although clinical decision support systems (CDSSs) are increasingly emphasized as one of the possible levers for improving care, they are still not widely used due to different barriers, such as doubts about systems’ performance, their complexity and poor design, practitioners’ lack of time to use them, poor computer skills, reluctance to use them in front of patients, and deficient integration into existing workflows. While several studies on CDSS exist, there is a need for additional high-quality studies using large samples and examining the differences between outcomes following a decision based on CDSS support and those following decisions without this kind of information. Even less is known about the effectiveness of a CDSS that is delivered during a grand round routine and with the help of socially assistive humanoid robots (SAHRs). In this study, 200 patients will be randomized into a Control Group (i.e. standard care) and an Intervention Group (i.e. standard care and novel CDSS delivered via a SAHR). Health care quality and Quality of Life measures will be compared between the two groups. Additionally, approximately 22 clinicians, who are also active researchers at the University Clinical Center Maribor, will evaluate the acceptability and clinical usability of the system. The results of the proposed study will provide high-quality evidence on the effectiveness of CDSS systems and SAHR in the grand round routine.

Keywords

Clinical decision support system, digital health intervention, socially assistive humanoid robots, grand rounds, healthcare quality, quality of life

Submission date: 16 March 2022; Acceptance date: 10 September 2022

Introduction

Clinical practice and clinical decision-making go hand in hand; it is virtually impossible to conduct work as a clinician and avoid making decisions that require practical application of clinical knowledge, problem-solving, weighing of probabilities, and balancing the risks and benefits of these decisions.¹ Although decision-making is an inherent part of clinical practice, it is notoriously complex, as it consists of several, often complex and multi-target interventions, that need to be performed within the bounds of human capabilities as well as limits imposed by the modern health care system.² Some of the specific challenges include (but are not limited to) the pressure to find...
the optimal solution, clinicians’ tiredness and uncertainty, proneness to heuristics and biases, information overload, inadequate staffing, and time constraints.\(^3,^4\) Hence, it is not very surprising that a range of errors with varying severity can occur.\(^5\) During hospitalization, specifically, these most often include medication errors, such as dosing errors and medication omissions.\(^6,^7\)

Computerized clinical decision support systems (CDSSs) represent a paradigm shift in improving complex healthcare today.\(^8\) CDSSs refer to any electronic system designed to aid clinical decision-making, in which characteristics of patients are used to generate patient-specific assessments or recommendations that are then presented to clinicians for consideration.\(^9\) CDSSs are increasingly emphasized as one of the possible levers for improving care. For example, they have previously been linked to reduced medication errors, better accessibility and visibility of data, and faster prescribing of medication and treatment.\(^10–13\) CDSS systems can be subdivided “knowledge-based” (i.e. rule-based) and “non-knowledge-based” (i.e. data-driven) with regards to how the medical knowledge is captured.\(^8,^14\) Knowledge-based systems are workflow-driven and depend on expert rules that are used to process input data in order to produce an action or output. The rules are based on the extensive, subject-specific, clinical knowledge taken from the medical literature (i.e. literature-based), clinicians, and experts (i.e. practice-based), or patient-directed evidence.\(^15\) The non-knowledge-based systems are case-driven, however, they still require a data source. In fact, large sets of labeled data are required to train the algorithms.\(^16\) Namely, the “decisions” in the non-knowledge-based systems do not follow expert medical knowledge but leverage artificial intelligence (AI), machine learning, or statistical pattern recognition.\(^8,^14\) The non-knowledge-based systems can simplify the knowledge acquisition and maintenance process.\(^17\) Such systems can even improve the accuracy and speed of diagnosis by analyzing complex patterns in high-dimensional data well beyond human performance\(^18–20\). However, in healthcare, where mistakes can cost human life, the non-explainable (i.e. black-box) nature of AI makes it unacceptable for clinicians and even regulators.\(^21\) In addition to doubts about systems, other barriers, such as lack of transportability and interoperability, their complexity and poor design (i.e. poor data quality and interpretation), privacy concerns and reluctance to use them in front of patients, poor computer skills and literacy, and deficient integration into existing workflows, prevent a wide adaption in practice.\(^8,^16,^22–24\).

As the benefits of CDSS can improve patient outcomes, it is vital to convert the barriers described above into facilitators of CDSSs’ use\(^25–27\). Hence, the present study protocol proposes the evaluation of a new system, developed with the aim to provide an information-rich, valid, safe, and easy-to-use tool that is well-integrated into the existing healthcare routine. The system will exploit patient-reported data, electronic health records (EHRs), and patient-reported outcomes (i.e. pain and psychological distress). The most prominent contribution of the proposed CDSS lies in its format of delivery and implementation. Specifically, the CDSS will be able to detect, as well as communicate, alarming situations (e.g. deviations in pain scores, heart rate, and blood pressure) during grand rounds and pre/post-operative care of patients with vascular and thoracic conditions. To this end, a fuzzy logic (FL)-based CDSS will be deployed. FL provides a transparent (explainable) and effective means for dealing with uncertainties in the health decision-making process.\(^28,^29\) The rules will be defined based on expert knowledge and already established clinical guidelines and observations. Namely, the diseases were chosen as they are highly prevalent, have a typically complicated course of the disease, as there are multiple treatment options available and a lot of input information must be monitored.\(^30\) Furthermore, the newly developed CDSS will provide intuitive visualizations of patients’ health-related data, including EHRs, health quality measures (i.e. pain, blood pressure, oxygenation, and heart rate), patient-reported data, and patient-reported outcomes. The health data will be structured in an interoperable HL7-FHIR format.\(^31\) The real-time access during the grand round routine is ensured with speech-enabled user interfaces delivered via a tablet attached to the socially assistive humanoid robot (SAHR), Pepper.\(^32\) While the uptake of SAHR in clinical practice is so far limited,\(^33,^34\) and to our best knowledge, there are no studies on the integration of CDSSs and social robotics yet, such innovative delivery could have several important benefits. In particular, it could make the use of a CDSS more effortless for clinicians (e.g. due to the robot being capable of movement, carrying the tablet, and offering assistance with queries in natural language) as well as more satisfactory and engaging for all involved stakeholders including patients.\(^34,^35\) It could serve as an enabler of real-time querying and visualization of patient data.\(^36\) Adding human characteristics to the CDSS could contribute to higher trust in the system.\(^33,^37,^38\)

We hypothesize that clinicians will accept the CDSS and recognize its clinical usability (H1). The use of CDSS will have a positive impact on health quality measures (H2) and the quality of life of patients (H3). In addition to our primary hypotheses, we aim to explore the impact of real-time access to the extended clinical background on diagnostic and treatment workflows for patients with vascular and thoracic diseases and conditions (R1).

Methods

Study design

The proposed study is designed as an experimental, prospective randomized controlled clinical trial. Participants
of the study, that is patients with vascular or thoracic diseases, and clinicians, will be recruited at the regional university clinical center. The study will be carried out in one-week intervals over a two-year period, with one-week wash-out period between each iteration. Clinicians will be participating in the study over the whole two-year period, while patients will be participating only during their stay at the hospital. During wash-out period, the CDSS and SAHR are not used in the departments. The study will be carried out and reported on individually for the two cohorts. At the end of the study, the results will be cross-compared to assess possible generalizability across surgery settings.

Patients admitted to vascular or thoracic surgery wards for an elective (non-emergency) procedure will be screened for eligibility regarding the inclusion and exclusion criteria. Eligible participants will then be informed about the study characteristics and asked to fill out an informed consent form. Those who will consent to participate in the study will participate for five days (one week) and will be randomized by the clinicians into:

- Intervention Group (CDSS delivered by SAHR is actively used), and
- Control Group (CDSS is not used; instead, only standard workflow and progression charts are utilized).

Blinding will be achieved by handling the same tools during the grand rounds. However, in the control group, the robot and tablet will not provide any information to clinicians. Blinding will be furthermore achieved by adhering to the usual workflow and paper progression charts with all patients in both groups. The study procedure is outlined in Figure 1.

At the enrollment (T1), patients will fill out the baseline questionnaires collecting patient demographic information, and assessing their perceived quality of life. The perceived quality of life is again measured at the end of the intervention (T2).

Each patient will be followed for three–five days, depending on the standardized care. During this period, health care quality measures, including health quality measures, blood pressure, oxygenation and heart rate, and pain, are collected for both groups two times a day. Blood pressure, oxygenation, and heart rate are measured in all in-patients, recorded daily (standard procedure) and recorded on a progression chart. In the intervention group, blood pressure, oxygenation, and heart rate measures are stored electronically and the CDSS is used to flag deviations from the standard, and alert the treating clinician. In the control group, the standard progression chart is used as per hospital protocol. The treating clinician is autonomous to decide to step up or modify antihypertensive treatment. Pain is measured in all in-patients on daily basis, two times a day (standard procedure), and recorded on a progression chart. In the intervention group, the pain level is stored electronically and CDSS is used to flag and alert the treating clinician on pain levels identified above anticipated. In the control group, the standard progression chart is used as per hospital protocol. The treating clinician is autonomous to decide to step up or modify analgetic treatment.

The participating clinicians will be asked to evaluate the clinical usability and provide answers on their acceptance of the CDSS system five times during the study (after the first iteration, after half a year, after the first year, after a year and a half, and after the last iteration).

Participants and recruitment

The proposed study intends to recruit two distinct samples: patients and clinicians. The patient sample will be composed of patients admitted to vascular surgery or thoracic surgery wards for an elective (non-emergency) procedure. Patients will need to be aged 18 years or above and willing to participate in the study. Exclusion criteria include emergency patients, patients already enrolled in other studies, patients with dementia, patients with special needs or appointed guardians, and patients allocated to an intensive step-down unit and/or regimen. The sample of clinicians will be composed of clinicians participating in a grand round routine within the vascular surgery or the thoracic surgery ward. Again, only employees aged 18 years or above, who will have signed a consent form, will be eligible to participate in the study.

There will be a pool of 400 eligible participants (200 per ward) available for inclusion in this study. Vascular and Thoracic Surgery Wards at the University Clinical Center Maribor treat over 4000 individuals annually and it is estimated that roughly 1400 individuals meet the inclusion criteria. However, based on the fact that, in general, at most 30% of participants (or less) consent to the clinical study, we assume that the final number of subjects willing to participate will be much lower. Regarding sample size requirements for the present study, public registries of clinical trials were reviewed. ClinicalTrials.gov returned 12 studies using the keywords “Vascular Diseases,” “CDSS,” and “randomized clinical trial,” while ISRCTN and EU Clinical Trials Registers returned no studies under the same conditions. These studies primarily focused on Stroke Prevention, CVD Risk Factor Control, and Hypertension. These studies differed substantially in the number of participants enrolled, from 40 to 400,000 participants per study. Considering the tertiary settings, the studies involved between 40 and 400 participants, with an average of 80 patients. In this study, 100 patients treated for Vascular Diseases will be enrolled in the study. Only one study was found on ClinicalTrials.gov using keywords
“Thoracic Diseases,” “CDSS,” and “randomized clinical trial” involving 47 participants, while ISRCTN and EU Clinical Trials Registers returned no studies under the same conditions. In this study, 100 patients treated for Thoracic Diseases will be enrolled. Additionally, we also performed calculations using the G*Power software. Patient-related analyses will predominantly be based on the ANOVA repeated measures statistical test with the within-between interaction (two groups, two measurements). As we hypothesize a small effect size \( (f = 0.10) \) and intend to use a conventional significance threshold and power \( (\alpha = 0.05, 1-\beta = 0.80) \), the total sample size needed to detect the effects is 200 participants.

The clinicians will be included in the study with the within-subjects design, whereby they will fill out the questionnaires five times during the study period. As such, we performed the sample size calculation in the G*Power software, choosing the Repeated Measures ANOVA test as the statistical test, entering a medium effect size \( (f = 0.25) \), and choosing a conventional significance threshold and power \( (\alpha = 0.05, 1-\beta = 0.80) \). Such calculations suggest that at least 21 clinicians must be recruited overall.
Measures

Testing the primary hypotheses will require the measurement of several outcomes, namely clinical usability and acceptance of the CDSS system from the clinicians’ perspective. To evaluate the clinical usability of the CDSS system, a System Usability Scale (SUS)\textsuperscript{40,41} will be used. SUS is a frequently used measure for assessing the subjective usability of systems and products. Several studies proved its psychometric quality in several languages. It consists of 10 items (e.g. “I thought the system was easy to use.”), which are answered on a five-point scale from one (strongly disagree) to five (strongly agree).\textsuperscript{42}

To evaluate the acceptance of the CDSS system, a unified theory of acceptance and use of technology and its extension will be used (UTAUT\textsuperscript{43} and UTAUT2\textsuperscript{44}). The UTAUT model proposes four constructs regarding technology acceptance, that is performance expectancy, effort expectancy, social influence, and facilitating conditions. The extended version of the model, UTAUT2, incorporates additional three constructs, that is hedonic motivation, price value, and habit.\textsuperscript{44} As there is no one specific questionnaire based on the UTAUT and UTAUT2 models, but rather they are developed for specific studies and technologies assessed, this approach will be followed also in the present study in the co-creation phase, where the questionnaire will be defined in detail.

The secondary objective of the study is to evaluate the possible impact of the CDSS on health quality measures and quality of life of patients. To assess health quality measures, blood pressure, oxygenation and heart rate will be recorded daily, two times per day for all patients. In addition, pain levels will be assessed as part of the health quality measures. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between “no pain” and “worst pain.”\textsuperscript{45} VAS was evaluated with no statistically significant difference observed between the paper and laptop computer platforms. Thus, VAS can be adapted to digital and paper formats.

Finally, to evaluate the potential impact of CDSS on quality of life the EQ-5D-3L instrument\textsuperscript{46} is used in both groups of patients. The EQ-5D-3L’s descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-3L tool essentially consists of two pages: the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS).\textsuperscript{47} The Slovenian version was validated by Prevolnik-Rupel with a representative sample of 3000 adults.\textsuperscript{48}

Plan of analysis

Preliminary analyses

We will use the IBM SPSS Statistics 26 program for statistical analysis. In the first step, we will clean the dataset and exclude participants with missing data on any of the measurement points and within questionnaires, with more than 20% of missing values. We will also perform basic psychometric analyses of the questionnaires, namely the factor or other appropriate analyses to evaluate the internal structure of the questionnaires and analysis of reliability as internal consistency (coefficient $\alpha$) and calculate the scores in accordance with the scoring instructions.

In the next step, we will perform basic descriptive analyses (means and standard deviations) and check the assumptions of the chosen statistical tests (such as the normality of the distribution assumption). This step will be followed by inferential tests, whereby results with a $p$-value below .05 will be considered statistically significant.

Analyses of patient-related outcomes

The impact of CDSS use on the first patient-related outcome, that is health quality measures (H2), will primarily be analyzed with growth curve analyses.

The impact of CDSS use on the second patient-related outcome, that is perceived quality of life (H3), will primarily be analyzed with repeated-measure analysis of variance (ANOVA), with time as the within-subjects factor. Significant results will be followed up with pairwise post-hoc tests using the correction to adjust for multiple testing. All results will be accompanied by effect sizes.

Analyses of clinicians-related outcomes

Clinicians’ acceptance of the CDSS and its perceived clinical usability (H1) will be analyzed with two separate repeated-measure ANOVA, with time as the within-subjects factor. Significant results will be followed up with pairwise post-hoc tests using the correction to adjust for multiple testing. All results will be accompanied by effect sizes.

Other analyses

The additional research question (R1) will be assessed qualitatively through clinicians’ notes and observations given after the patient is released from hospital care.

Discussion

Despite the growing need and interest for digital computer-aided support and many machine learning algorithms for classification and inference leading to automated interpretation of clinical data, their large-scale uptake is progressing rather slowly.\textsuperscript{30,49,50} This is especially disconcerting since existing studies suggest CDSS can contribute to patient safety,\textsuperscript{7,51,52} adherence to clinical guidelines,\textsuperscript{53} and in management of patients on research/treatment protocols.\textsuperscript{54} Moreover, CDSSs can contribute to the optimization of
healthcare costs by decreasing inpatient length-of-stay and reducing test duplication, and can even serve as computerized “consultation” or filtering (i.e. diagnostic decision support systems). One of the plausible reasons for this gap is low user acceptance. In the past, clinicians were not involved in the design and were consequently hesitant to accept CDSSs leading to suboptimal implementation. Furthermore, most interventions appear to achieve small to moderate improvements with the risk to cause alert fatigue or physicians’ burnout. It remains an industry-wide challenge to provide credible evidence, therefore, hindering wider adoption.

Our study is hence designed to provide credible evidence on the impact of clinician-centric CDSS design and SAHR in the context of healthcare. More specifically, this study will provide crucial data on the effects of having access to extended clinical background on demand and within intuitive user interfaces delivered by SAHR during the grand round routine. As such, it will provide some answers regarding the practical value of deploying the solutions from a clinical perspective and their potential for improving health quality and quality of life among patients. At the same time, it seeks to investigate whether socially aware digital systems can reduce inpatient length of stay, increase medication efficacy, and reduce medication errors. We will conduct a rigorous study and use validated questionnaires to measure the outcomes. This will ensure the generation of high-quality evidence, on a large enough sample of patients and clinicians. Relevant recommendations and guidelines will be adhered to throughout the process. Special attention will be directed toward ethical considerations.

The proposed study is not without limitations. First, even though all surgery patients conforming to the inclusion criteria will be invited to participate in the study, it is plausible that only patients with more favorable attitudes towards technology will agree to participate in the study. This might lead to a sample that is generally younger and possibly favoring specific medical conditions. Second, due to the specific characteristics of vascular and thoracic surgery patients (e.g. length of hospitalization), their exposure to the modified routine will be somewhat short. Hence, the study will primarily focus on initial impact, whereas the trajectories of what happens over a more extended period (i.e. continued use), which can differ from initial reactions, will have to be explored in future studies. Lastly, in the present study, the new knowledge-based digital system will be limited to a few specific digital services, physical locations, one hospital, and decision support for two categories of diseases/conditions. Although capable of visualizing any clinical data, the clinician-centeredness and the FL support modules will be designed in collaboration with and around the needs of experts in the treatment and care of patients with the two specific conditions. This makes it difficult to provide general and final conclusions on the effectiveness of CDSS delivered with SAHR in hospitals.

**Contributorship:** IM and VF ensured funding for the study. All authors contributed to the conceptualization of the study. IM, NP, and AB drafted the study design. The original draft was written by IM, NP, and IM, NP, BM, and NK carried out background research. VF, AB, NK, SH, and DV defined the primary and secondary outcomes. NP, US, VF, and AB calculated the sample sizes to ensure statistical relevance. All authors contributed to reviewing and editing the manuscript. All authors read and approved the final manuscript.

**Declaration of conflicting interests:** The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding:** The study will be carried out within the HosmartAI project, Pilot #5, funded by European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016834. The funding source had no role in the design of this study and will not have a role beyond progress monitoring and evaluation of the quality of the project HosmartAI during the execution. The funding source will have no role in analyses or interpretation of the data of this clinical study, or the decision to submit results. This study or its results do not reflect the position or opinion of the European Commission.

**Ethical approval and consent to participate:** The methods will be performed in accordance with relevant guidelines and regulations and were approved Medical Ethics Commission (University Medical Center Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia; eticana.komisija@ukc-mb.si; +386 2 321 2489), on 15/12/2021, under ref. no.: UKC-MB-KME-77/21. Informed consent will be obtained in a written form, from each participant, and collected by nursing staff during recruitment.

**Guarantor:** The guarantor of this article is IM.

**ORCID iD:** Izidor Mlakar https://orcid.org/0000-0002-4910-1879

**References**

1. Hajjaj FM, Salek MS, Basra MKA, et al. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med; 103. Epub ahead of print 2010. DOI: 10.1258/jrsm.2010.100104.

2. Allender S, Hayward J, Gupta S, et al. Bayesian strategy selection identifies optimal solutions to complex problems using an example from GP prescribing. npj Digital Med; 3. Epub ahead of print 2020. DOI: 10.1038/s41746-019-0205-y.

3. Shafii L, Walton J, Blenkinsopp J, et al. Information overload in emergency medicine physicians: a multisite case study exploring the causes, impact, and solutions in Four North England national health service trusts. J Med Internet Res; 22. Epub ahead of print 2020. DOI: 10.2196/19126.
4. Loftus TJ, Tighe PJ, Filiberto AC, et al. Artificial intelligence and surgical decision-making. JAMA Surg; 155. Epub ahead of print 2020. DOI: 10.1001/jamasurg.2019.4917.

5. Jha AK, Larizgoitia I, Audera-Lopez C, et al. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf; 22. Epub ahead of print 2013. DOI: 10.1136/bmjqs-2012-001748.

6. Mulac A, Taxis K, Hagesaether E, et al. Severe and fatal medication errors in hospitals: findings from the Norwegian Incident Reporting System. Eur J Hosp Pharm. Epub ahead of print 2020. DOI: 10.1136/ehp-horm-2020-002298.

7. Ling OA, Kiong AGTH and Yew ICY. Detection of medication errors through medication history assessment during admission at general medical wards. J Pharm Pract. Epub ahead of print 2021. DOI: 10.1177/0897190020987127.

8. Sutton RT, Pincock D, Baumgart DC, et al. An overview of clinical decision support systems: benefits, risks, and strategies for success. npj Digital Med; 3. Epub ahead of print 2020. DOI: 10.1038/s41746-020-0221-y.

9. Kawamoto K, Houlihan CA, Balas EA, et al. Improving clinical practice using computer decision support systems: a systematic review of trials to identify features critical to success. Br Med J; 330. Epub ahead of print 2005. DOI: 10.1136/bmj.38398.500764.8f.

10. Bright TJ, Wong A, Dhurjati R, et al. Effect of clinical decision-support systems: a systematic review. Ann Intern Med; 157. Epub ahead of print 2012. DOI: 10.7326/0003-4819-157-1-201207030-00450.

11. Mogharbel A, Dowding D and Ainsworth J. Physicians’ use of the computerized physician order entry system for medication prescribing: systematic review. JIMR Med Inform; 9. Epub ahead of print 2021. DOI: 10.2196/22923.

12. Naci H, Salcher-Konrad M, McGuire A, et al. Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. npj Digital Med; 2. Epub ahead of print 2019. DOI: 10.1038/s41746-019-0085-1.

13. Bilici E, Despotou G and Arvanitis TN. The use of computer-interpretable clinical guidelines to manage care complexities of patients with multimorbid conditions: a review. Digital Health; 4. Epub ahead of print 2018. DOI: 10.1177/2055207618804927.

14. Papadopoulos P, Soffano M, Chaudry Y, et al. A systematic review of technologies and standards used in the development of rule-based clinical decision support systems. Health Technol (Berl) 2022; 12: 713–727.

15. Sim I, Gorman P, Greenes RA, et al. Clinical decision support systems for the practice of evidence-based medicine. J Am Med Inform Assoc; 8. Epub ahead of print 2001. DOI: 10.1136/jama.2001.0080527.

16. Capobianco E. Data-driven clinical decision processes: it’s time. J Transl Med; 17. Epub ahead of print 2019. DOI: 10.1186/s12967-019-1795-5.

17. Stojkovska LA and Loksowska SC. Clinical decision support systems: medical knowledge acquisition and representation methods. In: 2010 IEEE international conference on electron/ information technology, EIT2010, 2010. Epub ahead of print 2010. DOI: 10.1109/EIT.2010.5612183.

18. Soguero-Ruiz C, Fei WME, Jenssen R, et al. Data-driven temporal prediction of surgical site infection. In AMIA Annual Symposium Proceedings, 2015.

19. Velickovski F, Ceccaroni L, Roca J, et al. Clinical decision support systems (CDSS) for preventive management of COPD patients. J Transl Med; 12. Epub ahead of print 2014. DOI: 10.1186/1479-5876-12-S2-S9.

20. Fazi MB. Beyond human: deep learning, explainability and representation. Theory Cult Soc; 38. Epub ahead of print 2021. DOI: 10.1177/0739933220987127.

21. Shortlife EH and Sepulveda MJ. Clinical decision support in the era of artificial intelligence. JAMA - J Am Med Assoc; 320. Epub ahead of print 2018. DOI: 10.1001/jama.2018.17163.

22. Devaraj S, Sharma SK, Fausto DJ, et al. Barriers and facilitators to clinical decision support systems adoption: a systematic review. J Bus Adm Res; 3. Epub ahead of print 2014. DOI: 10.5430/jbar.v3n2p36.

23. McGraw D and Mandl KD. Privacy protections to encourage use of health-relevant digital data in a learning health system. npj Digital Med; 4. Epub ahead of print 2021. DOI: 10.1038/s41746-020-00362-8.

24. Jando T. WHO guidance for digital health: what it means for researchers. Digital Health; 6. Epub ahead of print 2020. DOI: 10.1177/2055207619898984.

25. Taheri Moghadam S, Sadooghi F, Velayati F, et al. The effects of clinical decision support system for prescribing medication on patient outcomes and physician practice performance: a systematic review and meta-analysis. BMC Med Inform Decis Mak; 21. Epub ahead of print 2021. DOI: 10.1186/s12911-020-01376-8.

26. Ploegmakers KJ, Medlock S, Linn AJ, et al. Barriers and facilitors in using a clinical decision support system for fall risk management for older people: a European survey. Eur Geriatr Med. Epub ahead of print 2022. DOI: 10.1007/s41999-021-00599-w.

27. Guo C, Ashrafiyan H, Ghafor S, et al. Challenges for the evaluation of digital health solutions—a call for innovative evidence generation approaches. npj Digital Med; 3. Epub ahead of print 2020. DOI: 10.1038/s41746-020-00314-2.

28. Impota G, Mazzella V, Vecchione D, et al. Fuzzy logic-based clinical decision support system for the evaluation of renal function in post-transplant patients. J Eval Clin Pract; 26. Epub ahead of print 2020. DOI: 10.1111/jep.13302.

29. Chimapatu R, Hragas H, Starkey A, et al. Explainable AI and fuzzy logic systems. Lecture Notes in Computer Science (including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 2018. Epub ahead of print 2018. DOI: 10.1007/978-3-030-04070-3_1.

30. Ubbink DT and Koellemay MJW. Shared decision making in vascular surgery. Why would you? Eur J Vasc Endovasc Surg; 56. Epub ahead of print 2018. DOI: 10.1016/j.evs.2018.06.042.

31. Saripalle R, Runyan C and Russell M. Using HL7 FHIR to achieve interoperability in patient health record. J Biomed Inform; 94. Epub ahead of print 2019. DOI: 10.1016/j.jbi.2019.103188.

32. Softbank. Pepper - the humanoid and programmable robot, https://www.softbankrobotics.com/emea/en/pepper

33. Chen SC, Jones C and Moyle W. Health professional and workers attitudes towards the use of social robots for older adults in long-term care. Int J Soc Robot; 12. Epub ahead of print 2020. DOI: 10.1007/s12369-019-00613-z.

34. Buchanan C, Howitt ML, Wilson R, et al. Predicted influences of artificial intelligence on the domains of nursing: scoping
46. Rabin R and de Charro F. EQ-5D: A measure of health status from the EuroQol Group. *Ann Med*. 2001. Epub ahead of print 2001. DOI: 10.3109/07853890109002087.

47. Brooks R, Boye KS and Slaap B. EQ-5D: a plea for accurate nomenclature. *J Patient-Rep Outcomes*; 4. Epub ahead of print 2020. DOI: 10.1186/s41687-020-00222-9.

48. Prevolnik Rupel V, Srakar A and Rand K. Valuation of EQ-5D-3L health states in Slovenia: VAS based and TTO based value sets. *Zdr Varst*; 59. Epub ahead of print 2020. DOI: 10.2478/zjh-2020-0002.

49. Kwan JL, Lo L, Ferguson J, et al. Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials. *BMJ*; 370. Epub ahead of print 2020. DOI: 10.1136/bmj.m3216.

50. van Baalen S, Boon M and Verhoef P. From clinical decision support to clinical reasoning support systems. *J Eval Clin Pract*. 2021. Epub ahead of print 2021. DOI: 10.1111/jep.13541.

51. Helmons PJ, Suijkerbuijk BO, Panday PVN, et al. Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis. *J Am Med Inform Assoc*; 22. Epub ahead of print 2015. DOI: 10.1093/jamia/ocu010.

52. Mahoney CD, Berard-Collins CM, Coleman R, et al. Effects of an integrated clinical information system on medication safety in a multi-hospital setting. *Am J Health-Syst Pharm*; 64. Epub ahead of print 2007. DOI: 10.2146/ajhp060617.

53. Shah S, Switzer S, Shippie ND, et al. Implementation of an anticoagulation practice guideline for COVID-19 via a clinical decision support system in a large academic health system and its evaluation: Observational study. *JMIR Med Inform*; 9. Epub ahead of print 2021. DOI: 10.2196/30743.

54. Lipton JA, Barendse RJ, Schinkel AFL, et al. Impact of an alerting clinical decision support system for glucose control on protocol compliance and glycemic control in the intensive cardiac care unit. *Diabetes Technol Ther*; 13. Epub ahead of print 2011. DOI: 10.1089/dia.2010.0100.

55. Kawamoto K and McDonald CJ. Designing, conducting, and reporting clinical decision support studies: recommendations and call to action. *Ann Intern Med*; 172. Epub ahead of print 2020. DOI: 10.7326/M19-0875.

56. Khairat S, Marc D, Crosby W, et al. Reasons for physicians not adopting clinical decision support systems: critical analysis. *JMIR Med Inform*; 20. Epub ahead of print 2018. DOI: 10.2196/medinfrom.8912.

57. Andtfolk M, Nyholm L, Eide H, et al. Attitudes toward the use of humanoid robots in healthcare—a cross-sectional study. *AI Soc*. Epub ahead of print 2021. DOI: 10.1007/s10460-021-01271-4.

58. Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. *J Cardiovasc Dev Dis*; 6. Epub ahead of print 2019. DOI: 10.3390/jcd6020019.

59. Marasinghe KM. Computerised clinical decision support systems to improve medication safety in long-term care homes: a systematic review. *BMJ Open*; 5. Epub ahead of print 2015. DOI: 10.1136/bmjopen-2014-006539.